drug · protein
vosoritide
Marketedupdated 3mo agoby $BMRN BIOMARIN PHARMACEUTICAL INC🔗 ChEMBL
Approvedcommunity read0 votes
Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for achondroplasia and bone disease and 2 investigational indications.
targets
Atrial natriuretic peptide receptor 2
all catalysts(0)
nothing on the calendar yet
Trials studying vosoritide
- phase2A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
- phase3Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
- phase2A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
- phase2A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia
- phase2A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
- phase3Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
- phase3Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 20, 2026
66 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (24)
- Jul 11, 2042method-of-use (U-3927)US 12233106
- Jul 11, 2042method-of-use (U-3927)US 12233106
- Jul 11, 2042method-of-use (U-3927)US 12233106
- Aug 1, 2036formulationUS 10646550
- Aug 1, 2036formulationUS 10646550
- Aug 1, 2036formulationUS 10646550
- Aug 1, 2036formulationUS 11590204
- Aug 1, 2036formulationUS 11590204
- Aug 1, 2036formulationUS 11590204
- Aug 1, 2036method-of-use (U-3927)US 11911446
- Aug 1, 2036method-of-use (U-3927)US 11911446
- Aug 1, 2036method-of-use (U-3927)US 11911446
- Aug 1, 2036formulationUS 12514906
- Aug 1, 2036formulationUS 12514906
- Aug 1, 2036formulationUS 12514906
- Aug 1, 2036formulationUS 9907834
- Aug 1, 2036formulationUS 9907834
- Aug 1, 2036formulationUS 9907834
- Jun 11, 2030compositionUS 81982423.8y
- Jun 11, 2030compositionUS 81982423.8y
- Jun 11, 2030compositionUS 81982423.8y
- May 20, 2030method-of-use (U-3927)US RE482673.8y
- May 20, 2030method-of-use (U-3927)US RE482673.8y
- May 20, 2030method-of-use (U-3927)US RE482673.8y
FDA exclusivities (12)
- Oct 20, 2030ODE-449Orphan Drug (7y)4.2y
- Oct 20, 2030ODE-449Orphan Drug (7y)4.2y
- Oct 20, 2030ODE-449Orphan Drug (7y)4.2y
- Nov 19, 2028ODE-387Orphan Drug (7y)2.3y
- Nov 19, 2028ODE-387Orphan Drug (7y)2.3y
- Nov 19, 2028ODE-387Orphan Drug (7y)2.3y
- Nov 19, 2026NCENew Chemical Entity (5y)96d
- Nov 19, 2026NCENew Chemical Entity (5y)96d
- Nov 19, 2026NCENew Chemical Entity (5y)96d
- Oct 20, 2026NPPNew Product (3y)66d
- Oct 20, 2026NPPNew Product (3y)66d
- Oct 20, 2026NPPNew Product (3y)66d
News(3)
- Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccinesSome analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to level…biopharma_dive · 2d ago
- BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indicationBioMarin’s discontinued drug showed biomarker benefits in a Phase 3 study for ENPP1 deficiency but these failed to translate to clinical improvements.biospace · 4d ago
- BioMarin drug acquired in buyout misses goal in rare disease studyTested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects.biopharma_dive · 2mo ago
Data sources
last refreshed 34m ago
Found something off?
comments(0)
5-min edit window · permanent after that